Profile: Accuray Inc (ARAY.O)
26 May 2017
Accuray Incorporated, incorporated on February 22, 2001, is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. It develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its suite of products includes the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. The Company's technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver a range of treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
The CyberKnife Systems
The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. Treatment with the CyberKnife Systems requires no anesthesia, and treatment sessions are done on an outpatient basis. The CyberKnife Systems deliver treatments for intra- and extra-cranial disease sites throughout the body, including prostate, lung, brain, spine, liver, pancreas and kidney. The CyberKnife M6 Series System is available with the InCise Multileaf Collimator (InCise MLC). The Company's radiosurgery products are the CyberKnife Systems, which include the CyberKnife M6 Series with configuration options of fixed collimators plus the Iris Variable Aperture Collimator (FI), fixed collimators plus the InCise MLC (FM) and fixed collimators plus the Iris Variable Aperture Collimator plus the InCise MLC (FIM). Its configurations of CyberKnife Systems include The CyberKnife M6 Series with configurations of FI, FM and FIM. The CyberKnife M6 Series includes disease-specific tracking and treatment delivery solutions for brain, spine, lung and prostate tumors.
The TomoTherapy Systems
The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA. These systems consist of radiation therapy systems used by healthcare professionals in the treatment of a range of cancer types. The TomoTherapy System is a radiation therapy platform designed for image-guided intensity-modulated radiation therapy (IG-IMRT). Based on a ring gantry computed tomography (CT) scanner platform, the TomoTherapy System provides delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified direct beam angles. The TomoTherapy Systems are capable of treating various radiation therapy indications, including breast, prostate, lung, and head and neck cancers, in addition to treatments, such as total marrow irradiation. The TomoTherapy System is the Radixact that includes various options, which include TomoHelical, TomoDirect and TomoEdge dynamic jaws.
The Company competes with Elekta AB, Varian Medical Systems, Inc., Mitsubishi Heavy Industries, BrainLAB AG and ViewRay Inc.
1310 Chesapeake Ter
SUNNYVALE CA 94089-1100
Company Web Links
- BRIEF-Accuray reports prelim data from phase I trial of breast cancer cure treated with Cyberknife System
- BRIEF-Accuray Q3 loss per share $0.06
- BRIEF-Brian Grossman reports 5 pct passive stake in Accuray Inc as of March 6 - SEC filing
- BRIEF-Accuray on March 10, co entered into an amendment to financing agreement dated as of Jan. 11, 2016
- BRIEF-Accuray posts Q2 loss per share $0.11